Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study

American Journal of Hematology

Volumn 91, Issue 12, 2016, Pages 1246-1251

  Benhamou, Ygal ^a,b,c   Paintaud, Gilles ^d   Azoulay, Elie ^c,e,f   Poullin, Pascale ^c,g   Galicier, Lionel ^c,e,f   Desvignes, Céline ^d   Baudel, Jean Luc ^c,h   Peltier, Julie ⁱ   Mira, Jean Paul ^c,f,j   Pène, Frédéric ^c,f,j   Presne, Claire ^c,k   Saheb, Samir ^c,l   Deligny, Christophe ^m   Rousseau, Alexandra ^c,h   Féger, Frédéric ^c,h   Veyradier, Agnès ^c,f,n   Coppo, Paul ^c,o  

^a HÔPITAL CHARLES NICOLLE   (France)

^b Université Normandie de Rouen   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g Hôpital de Marseille Conception   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ HÔPITAL TENON   (France)

^j AP HP ^*  (France)

^k AMIENS UNIVERSITY HOSPITAL   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m CHU de Fort de France   (France)

ⁿ HÔPITAL LARIBOISIÈRE   (France)

^o INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DEXCHLORPHENIRAMINE; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

ADULT; ANAPHYLAXIS; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; ENZYME ACTIVITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN DEFICIENCY; LEG PAIN; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PLASMA EXCHANGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; REMISSION; SKIN MANIFESTATION; STATISTICAL ANALYSIS; THORAX PAIN; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; LYMPHOCYTE DEPLETION; MIDDLE AGED; MORTALITY; PATHOLOGY; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

ADAMTS13 PROTEIN; ADULT; B-LYMPHOCYTES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTORICALLY CONTROLLED STUDY; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RITUXIMAB;

EID: 84995581864     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24559     Document Type: Article

References (35)

1. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325:398–403.
2. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393–397.
3. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:654–666.
4. Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: The French TMA reference center experience. PLoS One 2010;5:e10208.
5. Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: Current perspectives. J Blood Med 2014;5:15–23.
6. Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004;103:4514–4519.
7. Scheiflinger F, Knobl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003;102:3241–3243.
8. Feys HB, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010;116:2005–2010.
9. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011;118:1746–1753.
10. Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012;40:104–111.
11. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 2005;106:1932–1937.
12. Westwood JP, Webster H, McGuckin S, et al. Rituximab for thrombotic thrombocytopenic purpura: Benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013;11:481–490.
13. Hie M, Gay J, Galicier L, et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura: Experience of the French thrombotic microangiopathies reference center. Blood 2014;124:204–210.
14. Azzopardi N, Francois M, Laurent E, et al. Influence of plasma exchange on rituximab pharmacokinetics. Br J Clin Pharmacol 2013;76:486–488.
15. McDonald V, Manns K, Mackie IJ, et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010;8:1201–1208.
16. Puisset F, White-Koning M, Kamar N, et al. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 2013;76:734–740.
17. Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: Clinical efficacy and biologic studies. Blood 2012;119:3691–3697.
18. Gomez-Almaguer D, Solano-Genesta M, Tarin-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood 2010;116:4783–4785.
19. Pequeno-Luevano M, Villarreal-Martinez L, Jaime-Perez JC, et al. Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: Report of four cases. Hematology 2013;18:233–236.
20. Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008;93:930–933.
21. Coppo P, Veyradier A. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med 2012;41:e163–e176.
22. Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010;115:1500–1511. quiz 1662.
23. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012;158:323–335.
24. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007;109:2815–2822.
25. Blasco H, Lalmanach G, Godat E, et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods 2007;325:127–139.
26. Bresin E, Gastoldi S, Daina E, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 2009;101:233–238.
27. Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: Thought for the best use? Crit Rev Oncol Hematol 2007;62:43–52.
28. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005;45:792–801.
29. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): Ten-year experience at a single center. Arthritis Rheum 2012;64:3770–3778.
30. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262–268.
31. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156–2168.
32. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010;5:1394–1400.
33. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007;2:932–937.
34. Coppo P, Wolf M, Veyradier A, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006;132:66–74.
35. Coppo P, Bengoufa D, Veyradier A, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004;83:233–244.